Invenra offers flexible options including rapid bispecific discovery and comprehensive collaborative development partnerships. Learn About Our Partnership Offerings

The B-Body ® Platform is at the core of therapeutic antibody development at Invenra. It is a proven platform for bispecific antibody yield, efficient conventional purification, high solubility, …

Since our founding, we have developed an extensive and proprietary set of platform technologies to enable the discovery and development of novel therapies across a wide range of …

Jan 31, 2019 · Invenra’s Novel Antibody INV724 Receives Rare Pediatric Disease and Orphan Drug Designations from the US FDA for Neuroblastoma Treatment

Located in the thriving city of Madison, Wisconsin, we are committed to living our Core Values every day and advancing patient health. If you feel you would be a good fit to join the Invenra …

Apr 9, 2024 · Invenra Inc. Announces a Strategic Research Agreement with Astellas Pharma in Therapeutic Bispecific Antibody Discovery with Astellas Pharma, a global pharmaceutical …

Apr 2, 2024 · Invenra Inc. Announces a Strategic Collaboration with Catalent to Co-Discover Novel Bispecific ADCs lopment and Manufacturing Organization (CDMO) specializing in …

INV322 is a next generation anti-CTLA-4 x CD25 bispecific mAb developed using Invenra’s high-developability B-Body Platform. Using the SNIPER Bispecific approach, the antibody was …

Feb 28, 2017 · Invenra is a pre-clinical stage bio-pharmaceutical company focused on discovering the next generation of best-in-class biologics, with an emphasis on monoclonal antibodies …

Aug 16, 2021 · building blocks for potential future Exelixis biologics, including antibody-drug conjugates. Our expanded collaboration with Invenra accelerates and deepens our work …